Biopharma · FDA Approvals · Stock

OVID Ovid Therapeutics

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of…

Assets on file: OV329

Start live analysis of OVID Run 8-agent AI analysis Stock overview All sector events →

Catalyst calendar

Dated catalysts for OVID, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for OVID, newest first.

Instant stream — events appear as soon as they are filed.

Decision-grade

Oct 3, 2025

09:09 PM

OVIDOvid Therapeutics

Ovid reports positive Phase 1 topline for OV329 GABA-AT inhibitor

OV329 met all primary safety and tolerability endpoints with no ophthalmic changes. Multiple TMS biomarkers showed statistically significant GABA-AT inhibition that matched or exceeded published therapeutic doses of vigabatrin. The company plans to initiate a Phase 2a study in drug-resistant focal onset seizures in Q2 2026.

Topline resultsSEC 8-K Open record